BioScrip Inc. (NASDAQ:BIOS) shares were down 5.2% during trading on Tuesday . The company traded as low as $2.55 and last traded at $2.57, with a volume of 526,289 shares traded. The stock had previously closed at $2.71.

Separately, Zacks Investment Research cut BioScrip from a “hold” rating to a “sell” rating in a research report on Wednesday, May 11th.

The firm’s 50 day moving average is $2.63 and its 200-day moving average is $2.26. The firm’s market cap is $177.45 million.

BioScrip (NASDAQ:BIOS) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.05. During the same quarter in the prior year, the company posted ($0.17) earnings per share. The business earned $238.50 million during the quarter, compared to analyst estimates of $232.38 million. The company’s revenue was down 2.4% on a year-over-year basis. On average, equities research analysts predict that BioScrip Inc. will post ($0.20) EPS for the current fiscal year.

In other news, Director David W. Golding purchased 12,500 shares of the company’s stock in a transaction dated Friday, June 17th. The shares were purchased at an average price of $2.48 per share, with a total value of $31,000.00. Following the transaction, the director now directly owns 42,500 shares of the company’s stock, valued at $105,400. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Coliseum Capital Management, L purchased 4,200,000 shares of the company’s stock in a transaction dated Wednesday, June 22nd. The shares were purchased at an average cost of $2.00 per share, for a total transaction of $8,400,000.00. The disclosure for this purchase can be found here.

Other hedge funds and institutional investors have recently modified their holdings of the company. Gamco Investors INC. ET AL boosted its position in shares of BioScrip by 1.4% in the fourth quarter. Gamco Investors INC. ET AL now owns 864,850 shares of the company’s stock worth $1,513,000 after buying an additional 12,250 shares in the last quarter. Diamond Hill Capital Management Inc. boosted its position in shares of BioScrip by 2.5% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 3,055,476 shares of the company’s stock worth $5,347,000 after buying an additional 74,757 shares in the last quarter. Finally, Gabelli Funds LLC boosted its position in shares of BioScrip by 22.9% in the fourth quarter. Gabelli Funds LLC now owns 11,430,900 shares of the company’s stock worth $20,004,000 after buying an additional 2,132,060 shares in the last quarter.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.